TAT-10: Progress in the [At211]-Astatination of Antibodies by Nuclephilic Approaches Using Aryliodonium Salts Precursors

Kanazawa, Japan (UroToday.com) In this study, we develop a method for At211 radio-labeling based on aryliodonium salts and compare with the more conventional approach using arylstannane chemistry. We find improved yields of 43 +/- 2 % for aryliodonium compared with 20 +/- 5% for arylstannane.

We attribute this improvement to two factors: the stannane chemistry approach requires an extra purification step, and the iodonium process uses the very stable At- while the stannane requires an At+ ion.

Presented By: Francois Guerand from Centre de Recherche en Cancerologie Nantes-Angers (CRCNA), Unite INSERM 892 – CNRS 6299, Nantes, France

Written By: William Carithers, Lawrence Berkeley National Laboratory

at the 10th International Symposium on Targeted Alpha Therapy (TAT-10)  May 31 - June 1, 2017 - Kanazawa, Japan.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe